These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19857957)

  • 1. Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.
    Kaehler KC; Sondak VK; Schadendorf D; Hauschild A
    Eur J Cancer; 2010 Jan; 46(1):41-6. PubMed ID: 19857957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).
    Eggermont AM; Bouwhuis MG; Kruit WH; Testori A; ten Hagen T; Yver A; Xu C
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):671-7. PubMed ID: 19621225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
    Loquai C; Nashan D; Hensen P; Luger TA; Grabbe S; Sunderkötter C; Schiller M
    Eur J Dermatol; 2008; 18(1):29-35. PubMed ID: 18086586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
    Hauschild A; Dummer R; Ugurel S; Kaehler KC; Egberts F; Fink W; Both-Skalsky J; Laetsch B; Schadendorf D
    Cancer; 2008 Sep; 113(6):1404-11. PubMed ID: 18615619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.
    Agarwala SS
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.
    Kimyai-Asadi A; Usman A
    J Am Acad Dermatol; 2000 Oct; 43(4):708-11. PubMed ID: 11004636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.
    Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Nishigori C
    Eur J Dermatol; 2018 Feb; 28(1):115-116. PubMed ID: 29171409
    [No Abstract]   [Full Text] [Related]  

  • 8. The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma.
    Trinh VA; Zobniw C; Hwu WJ
    Expert Opin Drug Saf; 2017 Aug; 16(8):933-940. PubMed ID: 28627943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferons in melanoma.
    Agarwala SS; Kirkwood JM
    Curr Opin Oncol; 1996 Mar; 8(2):167-74. PubMed ID: 8727310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
    Fusi A; Collette S; Busse A; Suciu S; Rietz A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
    Eur J Cancer; 2009 Dec; 45(18):3189-97. PubMed ID: 19793643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on PEG-interferon α-2b as adjuvant therapy in melanoma.
    Di Trolio R; Simeone E; Di Lorenzo G; Grimaldi AM; Romano A; Ayala F; Caracò C; Mozzillo N; Ascierto PA
    Anticancer Res; 2012 Sep; 32(9):3901-9. PubMed ID: 22993335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
    J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma.
    Vaishampayan UN; Heilbrun LK; Marsack C; Smith DW; Flaherty LE
    Anticancer Drugs; 2007 Nov; 18(10):1221-6. PubMed ID: 17893524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
    Bouwhuis MG; Suciu S; Testori A; Kruit WH; Salès F; Patel P; Punt CJ; Santinami M; Spatz A; Ten Hagen TL; Eggermont AM
    J Clin Oncol; 2010 May; 28(14):2460-6. PubMed ID: 20385998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?
    Sondak VK; Flaherty LE
    Lancet; 2008 Jul; 372(9633):89-90. PubMed ID: 18620932
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.
    Sondak VK; Liu PY; Flaherty LE; Fletcher WS; Periman P; Gandara DR; Taylor SA; Balcerzak SP; Meyskens FL
    Cancer J Sci Am; 1999; 5(1):41-7. PubMed ID: 10188060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current aspects of adjuvant therapy of malignant melanoma].
    Kähler KC; Egberts F; Hauschild A
    Hautarzt; 2010 Jun; 61(6):523-31; quiz 532-3. PubMed ID: 20512304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
    Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: pegylated interferons: chemical and clinical differences.
    Foster GR
    Aliment Pharmacol Ther; 2004 Oct; 20(8):825-30. PubMed ID: 15479353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review.
    Ascierto PA; Gogas HJ; Grob JJ; Algarra SM; Mohr P; Hansson J; Hauschild A
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):149-61. PubMed ID: 22874771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.